MicroRNA Regulation of Atherosclerosis

Circulation Research

Volumn 118, Issue 4, 2016, Pages 703-720

  Feinberg, Mark W ^a   Moore, Kathryn J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; coronary artery disease; lipoproteins; microRNAs; vascular cell adhesion molecule

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; MICRORNA; MICRORNA 10A; MICRORNA 126; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 155; MICRORNA 181B; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 222; MICRORNA 29; MICRORNA 30 5P; MICRORNA 663; MICRORNA 712; UNCLASSIFIED DRUG; CYTOKINE; GENETIC MARKER;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIUM CELL; GENE CONTROL; HOMEOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MUSCLE FUNCTION; NEUTROPHIL CHEMOTAXIS; PHENOTYPE; PRIORITY JOURNAL; REMISSION; UNSTABLE ANGINA PECTORIS; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; VASCULITIS; ANIMAL; ARTERY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC MARKER; GENETIC SCREENING; GENETICS; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CYTOKINES; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENETIC TESTING; GENETIC THERAPY; HUMANS; LIPOPROTEINS; MICRORNAS; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

EID: 84959064263     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306300     Document Type: Article

References (182)

1. Hansson GK, Libby P, Tabas I., Inflammation and plaque vulnerability. J Intern Med 2015 278 483 493. doi: 10.1111/joim.12406.
2. Bartel DP., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 281 297
3. Ambros V., The functions of animal microRNAs. Nature 2004 431 350 355. doi: 10.1038/nature02871.
4. Krol J, Loedige I, Filipowicz W., The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010 11 597 610. doi: 10.1038/nrg2843.
5. Bartel DP., MicroRNAs: target recognition and regulatory functions. Cell 2009 136 215 233. doi: 10.1016/j.cell.2009.01.002.
6. Guo H, Ingolia NT, Weissman JS, Bartel DP., Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010 466 835 840. doi: 10.1038/nature09267.
7. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R., Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006 20 515 524. doi: 10.1101/gad.1399806.
8. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP., The impact of microRNAs on protein output. Nature 2008 455 64 71. doi: 10.1038/nature07242.
9. Friedman RC, Farh KK, Burge CB, Bartel DP., Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009 19 92 105. doi: 10.1101/gr.082701.108.
10. Landthaler M, Yalcin A, Tuschl T., The human DiGeorge syndrome critical region gene 8 and Its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004 14 2162 2167. doi: 10.1016/j.cub.2004.11.001.
11. Okamura K, Ishizuka A, Siomi H, Siomi MC., Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev 2004 18 1655 1666. doi: 10.1101/gad.1210204.
12. Esau C, Davis S, Murray SF, miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006 3 87 98. doi: 10.1016/j.cmet.2006.01.005.
13. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S., LNA-mediated microRNA silencing in non-human primates. Nature 2008 452 896 899. doi: 10.1038/nature06783.
14. Elmén J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, Hedtjärn M, Hansen JB, Hansen HF, Straarup EM, McCullagh K, Kearney P, Kauppinen S., Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008 36 1153 1162. doi: 10.1093/nar/gkm1113.
15. Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, Palmisano BT, Tabet F, Cui HL, Rye KA, Sethupathy P, Remaley AT., MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci USA 2014 111 14518 14523. doi: 10.1073/pnas.1215767111.
16. Vickers KC, Shoucri BM, Levin MG, Wu H, Pearson DS, Osei-Hwedieh D, Collins FS, Remaley AT, Sethupathy P., MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 2013 57 533 542. doi: 10.1002/hep.25846.
17. Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM., MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013 19 892 900. doi: 10.1038/nm.3200.
18. Goedeke L, Rotllan N, Canfrán-Duque A, Aranda JF, Ramírez CM, Araldi E, Lin CS, Anderson NN, Wagschal A, de Cabo R, Horton JD, Lasunción MA, Näär AM, Suárez Y, Fernández-Hernando C., MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med 2015 21 1280 1289. doi: 10.1038/nm.3949.
19. Wagschal A, Najafi-Shoushtari SH, Wang L, Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med 2015 21 1290 1297. doi: 10.1038/nm.3980.
20. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N., HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 2008 7 365 375. doi: 10.1016/j.cmet.2008.03.001.
21. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, Leclercq IA, MacDougald OA, Bommer GT., Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010 285 33652 33661. doi: 10.1074/jbc.M110.152090.
22. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, Marusawa H, Iwanaga Y, Hasegawa K, Yokode M, Kimura T, Kita T., MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010 107 17321 17326. doi: 10.1073/pnas.1008499107.
23. Marquart TJ, Allen RM, Ory DS, Baldán A., miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 2010 107 12228 12232. doi: 10.1073/pnas.1005191107.
24. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Näär AM., MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010 328 1566 1569. doi: 10.1126/science.1189123.
25. Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernández-Hernando C., MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010 328 1570 1573. doi: 10.1126/science.1189862.
26. Rayner KJ, Esau CC, Hussain FN, Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011 478 404 407. doi: 10.1038/nature10486.
27. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ., Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011 121 2921 2931. doi: 10.1172/JCI57275.
28. Ramirez CM, Dávalos A, Goedeke L, Salerno AG, Warrier N, Cirera-Salinas D, Suárez Y, Fernández-Hernando C., MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol 2011 31 2707 2714. doi: 10.1161/ATVBAHA.111.232066.
29. Sun D, Zhang J, Xie J, Wei W, Chen M, Zhao X., MiR-26 controls LXR-dependent cholesterol efflux by targeting ABCA1 and ARL7. FEBS Lett 2012 586 1472 1479. doi: 10.1016/j.febslet.2012.03.068.
30. Kim J, Yoon H, Ramírez CM, Lee SM, Hoe HS, Fernández-Hernando C, Kim J., MiR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression. Exp Neurol 2012 235 476 483. doi: 10.1016/j.expneurol.2011.11.010.
31. de Aguiar Vallim TQ, Tarling EJ, Kim T, Civelek M, Baldán Á Esau C, Edwards PA., MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor. Circ Res 2013 112 1602 1612. doi: 10.1161/CIRCRESAHA.112.300648.
32. Ramírez CM, Goedeke L, Rotllan N, Yoon JH, Cirera-Salinas D, Mattison JA, Suárez Y, de Cabo R, Gorospe M, Fernández-Hernando C., MicroRNA 33 regulates glucose metabolism. Mol Cell Biol 2013 33 2891 2902. doi: 10.1128/MCB.00016-13.
33. Wang L, Jia XJ, Jiang HJ, Du Y, Yang F, Si SY, Hong B., MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol Cell Biol 2013 33 1956 1964. doi: 10.1128/MCB.01580-12.
34. Hu Z, Shen WJ, Kraemer FB, Azhar S., MicroRNAs 125a and 455 repress lipoprotein-supported steroidogenesis by targeting scavenger receptor class B type I in steroidogenic cells. Mol Cell Biol 2012 32 5035 5045. doi: 10.1128/MCB.01002-12.
35. Rottiers V, Najafi-Shoushtari SH, Kristo F, Gurumurthy S, Zhong L, Li Y, Cohen DE, Gerszten RE, Bardeesy N, Mostoslavsky R, Näär AM., MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb Symp Quant Biol 2011 76 225 233. doi: 10.1101/sqb.2011.76.011049.
36. Rottiers V, Obad S, Petri A, Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med 2013 5 212ra162. doi: 10.1126/scitranslmed.3006840.
37. Allen RM, Marquart TJ, Albert CJ, Suchy FJ, Wang DQ, Ananthanarayanan M, Ford DA, Baldán A., miR-33 controls the expression of biliary transporters, and mediates statin-and diet-induced hepatotoxicity. EMBO Mol Med 2012 4 882 895. doi: 10.1002/emmm.201201228.
38. Horie T, Baba O, Kuwabara Y, MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/-mice. J Am Heart Assoc 2012 1 e003376. doi: 10.1161/JAHA.112.003376.
39. Rotllan N, Ramírez CM, Aryal B, Esau CC, Fernández-Hernando C., Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/-mice-brief report. Arterioscler Thromb Vasc Biol 2013 33 1973 1977. doi: 10.1161/ATVBAHA.113.301732.
40. Marquart TJ, Wu J, Lusis AJ, Baldán Á., Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2013 33 455 458. doi: 10.1161/ATVBAHA.112.300639.
41. Ouimet M, Ediriweera HN, Gundra UM, MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Invest 2015 2015. doi: 10.1172/JCI81676.
42. Horie T, Nishino T, Baba O, MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun 2013 4 2883. doi: 10.1038/ncomms3883.
43. Goedeke L, Salerno A, Ramírez CM, Guo L, Allen RM, Yin X, Langley SR, Esau C, Wanschel A, Fisher EA, Suárez Y, Baldán A, Mayr M, Fernández-Hernando C., Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med 2014 6 1133 1141. doi: 10.15252/emmm.201404046.
44. Karunakaran D, Richards L, Geoffrion M, Barrette D, Gotfrit RJ, Harper ME, Rayner KJ., Therapeutic inhibition of miR-33 promotes fatty acid oxidation but does not ameliorate metabolic dysfunction in diet-induced obesity. Arterioscler Thromb Vasc Biol 2015 35 2536 2543. doi: 10.1161/ATVBAHA.115.306404.
45. Libby P, Ridker PM, Hansson GK., Progress and challenges in translating the biology of atherosclerosis. Nature 2011 473 317 325. doi: 10.1038/nature10146.
46. Suárez Y, Wang C, Manes TD, Pober JS., Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol 2010 184 21 25. doi: 10.4049/jimmunol.0902369.
47. Sun X, Belkin N, Feinberg MW., Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep 2013 15 372. doi: 10.1007/s11883-013-0372-2.
48. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, Hunninghake GM, Vera MP, Blackwell TS, Baron RM, Feinberg MW, MICU Registry MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest 2012 122 1973 1990. doi: 10.1172/JCI61495.
49. Sun X, He S, Wara AK, Icli B, Shvartz E, Tesmenitsky Y, Belkin N, Li D, Blackwell TS, Sukhova GK, Croce K, Feinberg MW., Systemic delivery of microRNA-181b inhibits nuclear factor-κB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 2014 114 32 40. doi: 10.1161/CIRCRESAHA.113.302089.
50. Sun X, Sit A, Feinberg MW., Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc Med 2014 24 105 112. doi: 10.1016/j.tcm.2013.09.002.
51. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, Polykratis A, Kollias G, de Winther MP, Pasparakis M., Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab 2008 8 372 383. doi: 10.1016/j.cmet.2008.08.016.
52. Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D, Delgado-Olguin P, Cybulsky MI, Fish JE., MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 2013 5 949 966. doi: 10.1002/emmm.201202318.
53. Raitoharju E, Lyytikäinen LP, Levula M, Oksala N, Mennander A, Tarkka M, Klopp N, Illig T, Kähönen M, Karhunen PJ, Laaksonen R, Lehtimäki T., miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 2011 219 211 217. doi: 10.1016/j.atherosclerosis.2011.07.020.
54. Li K, Ching D, Luk FS, Raffai RL., Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB-driven inflammation and atherosclerosis. Circ Res 2015 117 e1 e11. doi: 10.1161/CIRCRESAHA.117.305844.
55. Saba R, Sorensen DL, Booth SA., MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front Immunol 2014 5 578. doi: 10.3389/fimmu.2014.00578.
56. Davies PF, Polacek DC, Handen JS, Helmke BP, DePaola N., A spatial approach to transcriptional profiling: mechanotransduction and the focal origin of atherosclerosis. Trends Biotechnol 1999 17 347 351
57. Frangos SG, Gahtan V, Sumpio B., Localization of atherosclerosis: role of hemodynamics. Arch Surg 1999 134 1142 1149
58. Chiu JJ, Chien S., Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011 91 327 387. doi: 10.1152/physrev.00047.2009.
59. Chiu JJ, Chen CN, Lee PL, Yang CT, Chuang HS, Chien S, Usami S., Analysis of the effect of disturbed flow on monocytic adhesion to endothelial cells. J Biomech 2003 36 1883 1895
60. DePaola N, Davies PF, Pritchard WF Jr, Florez L, Harbeck N, Polacek DC., Spatial and temporal regulation of gap junction connexin43 in vascular endothelial cells exposed to controlled disturbed flows in vitro. Proc Natl Acad Sci USA 1999 96 3154 3159
61. Miao H, Hu YL, Shiu YT, Yuan S, Zhao Y, Kaunas R, Wang Y, Jin G, Usami S, Chien S., Effects of flow patterns on the localization and expression of VE-cadherin at vascular endothelial cell junctions: in vivo and in vitro investigations. J Vasc Res 2005 42 77 89. doi: 10.1159/000083094.
62. Yamawaki H, Pan S, Lee RT, Berk BC., Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest 2005 115 733 738. doi: 10.1172/JCI23001.
63. Wu W, Xiao H, Laguna-Fernandez A, Villarreal G Jr, Wang KC, Geary GG, Zhang Y, Wang WC, Huang HD, Zhou J, Li YS, Chien S, Garcia-Cardena G, Shyy JY., Flow-Dependent Regulation of Kruppel-Like Factor 2 Is Mediated by MicroRNA-92a. Circulation 2011 124 633 641. doi: 10.1161/CIRCULATIONAHA.110.005108.
64. Loyer X, Potteaux S, Vion AC, Guérin CL, Boulkroun S, Rautou PE, Ramkhelawon B, Esposito B, Dalloz M, Paul JL, Julia P, Maccario J, Boulanger CM, Mallat Z, Tedgui A., Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 2014 114 434 443. doi: 10.1161/CIRCRESAHA.114.302213.
65. Fang Y, Davies PF., Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol 2012 32 979 987. doi: 10.1161/ATVBAHA.111.244053.
66. Daniel JM, Penzkofer D, Teske R, Dutzmann J, Koch A, Bielenberg W, Bonauer A, Boon RA, Fischer A, Bauersachs J, van Rooij E, Dimmeler S, Sedding DG., Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury. Cardiovasc Res 2014 103 564 572. doi: 10.1093/cvr/cvu162.
67. Iaconetti C, Polimeni A, Sorrentino S, Sabatino J, Pironti G, Esposito G, Curcio A, Indolfi C., Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res Cardiol 2012 107 296. doi: 10.1007/s00395-012-0296-y.
68. Bonauer A, Carmona G, Iwasaki M, MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009 324 1710 1713. doi: 10.1126/science.1174381.
69. Hinkel R, Penzkofer D, Zühlke S, Fischer A, Husada W, Xu QF, Baloch E, van Rooij E, Zeiher AM, Kupatt C, Dimmeler S., Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. Circulation 2013 128 1066 1075. doi: 10.1161/CIRCULATIONAHA.113.001904.
70. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ., MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 2008 105 1516 1521. doi: 10.1073/pnas.0707493105.
71. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN., The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008 15 261 271. doi: 10.1016/j.devcel.2008.07.002.
72. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND., MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 2010 464 1196 1200. doi: 10.1038/nature08889.
73. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh MN, Lutgens E, Wang S, Olson EN, Schober A, Weber C., Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009 2 ra81. doi: 10.1126/scisignal.2000610.
74. Schober A, Nazari-Jahantigh M, Wei Y, Bidzhekov K, Gremse F, Grommes J, Megens RT, Heyll K, Noels H, Hristov M, Wang S, Kiessling F, Olson EN, Weber C., MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014 20 368 376. doi: 10.1038/nm.3487.
75. Harris TA, Yamakuchi M, Kondo M, Oettgen P, Lowenstein CJ., Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells. Arterioscler Thromb Vasc Biol 2010 30 1990 1997. doi: 10.1161/ATVBAHA.110.211706.
76. Zhou J, Li YS, Nguyen P, Wang KC, Weiss A, Kuo YC, Chiu JJ, Shyy JY, Chien S., Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ Res 2013 113 40 51. doi: 10.1161/CIRCRESAHA.113.280883.
77. Ruby JG, Jan CH, Bartel DP., Intronic microRNA precursors that bypass Drosha processing. Nature 2007 448 83 86. doi: 10.1038/nature05983.
78. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC., Mammalian mirtron genes. Mol Cell 2007 28 328 336. doi: 10.1016/j.molcel.2007.09.028.
79. Son DJ, Kumar S, Takabe W, Kim CW, Ni CW, Alberts-Grill N, Jang IH, Kim S, Kim W, Won Kang S, Baker AH, Woong Seo J, Ferrara KW, Jo H., The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun 2013 4 3000. doi: 10.1038/ncomms4000.
80. Hergenreider E, Heydt S, Tréguer K, Boettger T, Horrevoets AJ, Zeiher AM, Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler S., Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012 14 249 256. doi: 10.1038/ncb2441.
81. Climent M, Quintavalle M, Miragoli M, Chen J, Condorelli G, Elia L., TGFβ triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization. Circ Res 2015 116 1753 1764. doi: 10.1161/CIRCRESAHA.116.305178.
82. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF., MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci USA 2010 107 13450 13455. doi: 10.1073/pnas.1002120107.
83. Ni CW, Qiu H, Jo H., MicroRNA-663 upregulated by oscillatory shear stress plays a role in inflammatory response of endothelial cells. Am J Physiol Heart Circ Physiol 2011 300 H1762 H1769. doi: 10.1152/ajpheart.00829.2010.
84. Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, Zhang Q, Jiang Y, Huang LY, Tang YB, Yan GJ, Zhou JG., Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 2012 60 1407 1414. doi: 10.1161/HYPERTENSIONAHA.112.197301.
85. Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X, Liao YH., MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One 2012 7 e46082. doi: 10.1371/journal.pone.0046082.
86. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, Weber C, Schober A., MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012 122 4190 4202. doi: 10.1172/JCI61716.
87. Donners MM, Wolfs IM, Stöger LJ, van der Vorst EP, Pöttgens CC, Heymans S, Schroen B, Gijbels MJ, de Winther MP., Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One 2012 7 e35877. doi: 10.1371/journal.pone.0035877.
88. Zhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X, Pan X, Zhang L, Yan H., Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One 2012 7 e46551. doi: 10.1371/journal.pone.0046551.
89. Sun C, Wu MH, Yuan SY., Nonmuscle myosin light-chain kinase deficiency attenuates atherosclerosis in apolipoprotein E-deficient mice via reduced endothelial barrier dysfunction and monocyte migration. Circulation 2011 124 48 57. doi: 10.1161/CIRCULATIONAHA.110.988915.
90. Demolli S, Doebele C, Doddaballapur A, Lang V, Fisslthaler B, Chavakis E, Vinciguerra M, Sciacca S, Henschler R, Hecker M, Savant S, Augustin HG, Kaluza D, Dimmeler S, Boon RA., MicroRNA-30 mediates anti-inflammatory effects of shear stress and KLF2 via repression of angiopoietin 2. J Mol Cell Cardiol 2015 88 111 119. doi: 10.1016/j.yjmcc.2015.10.009.
91. Moore KJ, Sheedy FJ, Fisher EA., Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013 13 709 721. doi: 10.1038/nri3520.
92. Zhang M, Wu JF, Chen WJ, MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages. Atherosclerosis 2014 234 54 64. doi: 10.1016/j.atherosclerosis.2014.02.008.
93. Chen T, Huang Z, Wang L, Wang Y, Wu F, Meng S, Wang C., MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res 2009 83 131 139. doi: 10.1093/cvr/cvp121.
94. Yang K, He YS, Wang XQ, Lu L, Chen QJ, Liu J, Sun Z, Shen WF., MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett 2011 585 854 860. doi: 10.1016/j.febslet.2011.02.009.
95. Tian FJ, An LN, Wang GK, Elevated microRNA-155 promotes foam cell formation by targeting HBP1 in atherogenesis. Cardiovasc Res 2014 103 100 110. doi: 10.1093/cvr/cvu070.
96. Meiler S, Baumer Y, Toulmin E, Seng K, Boisvert WA., MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis. Arterioscler Thromb Vasc Biol 2015 35 323 331. doi: 10.1161/ATVBAHA.114.304878.
97. Banerjee S, Xie N, Cui H, Tan Z, Yang S, Icyuz M, Abraham E, Liu G., MicroRNA let-7c regulates macrophage polarization. J Immunol 2013 190 6542 6549. doi: 10.4049/jimmunol.1202496.
98. Yang J, Zhang Z, Chen C, Liu Y, Si Q, Chuang TH, Li N, Gomez-Cabrero A, Reisfeld RA, Xiang R, Luo Y., MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene 2014 33 3014 3023. doi: 10.1038/onc.2013.258.
99. Wang Z, Brandt S, Medeiros A, Wang S, Wu H, Dent A, Serezani CH., MicroRNA 21 is a homeostatic regulator of macrophage polarization and prevents prostaglandin E2-mediated M2 generation. PLoS One 2015 10 e0115855. doi: 10.1371/journal.pone.0115855.
100. Saha B, Bruneau JC, Kodys K, Szabo G., Alcohol-induced miR-27a regulates differentiation and M2 macrophage polarization of normal human monocytes. J Immunol 2015 194 3079 3087. doi: 10.4049/jimmunol.1402190.
101. Veremeyko T, Siddiqui S, Sotnikov I, Yung A, Ponomarev ED., IL-4/IL-13-dependent and independent expression of miR-124 and its contribution to M2 phenotype of monocytic cells in normal conditions and during allergic inflammation. PLoS One 2013 8 e81774. doi: 10.1371/journal.pone.0081774.
102. Banerjee S, Cui H, Xie N, Tan Z, Yang S, Icyuz M, Thannickal VJ, Abraham E, Liu G., miR-125a-5p regulates differential activation of macrophages and inflammation. J Biol Chem 2013 288 35428 35436. doi: 10.1074/jbc.M112.426866.
103. Vergadi E, Vaporidi K, Theodorakis EE, Doxaki C, Lagoudaki E, Ieronymaki E, Alexaki VI, Helms M, Kondili E, Soennichsen B, Stathopoulos EN, Margioris AN, Georgopoulos D, Tsatsanis C., Akt2 deficiency protects from acute lung injury via alternative macrophage activation and miR-146a induction in mice. J Immunol 2014 192 394 406. doi: 10.4049/jimmunol.1300959.
104. Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang CY, Zen K., Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol 2012 4 341 343. doi: 10.1093/jmcb/mjs044.
105. Lu S, Gao Y, Huang X, Wang X., Cantharidin exerts anti-hepatocellular carcinoma by miR-214 modulating macrophage polarization. Int J Biol Sci 2014 10 415 425. doi: 10.7150/ijbs.8002.
106. Zhuang G, Meng C, Guo X, Cheruku PS, Shi L, Xu H, Li H, Wang G, Evans AR, Safe S, Wu C, Zhou B., A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation 2012 125 2892 2903. doi: 10.1161/CIRCULATIONAHA.111.087817.
107. Liu G, Friggeri A, Yang Y, Park YJ, Tsuruta Y, Abraham E., miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci USA 2009 106 15819 15824. doi: 10.1073/pnas.0901216106.
108. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q, Johnson DS, Chen Y, O'Neill LA., Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010 11 141 147. doi: 10.1038/ni.1828.
109. Manoharan P, Basford JE, Pilcher-Roberts R, Neumann J, Hui DY, Lingrel JB., Reduced levels of microRNAs miR-124a and miR-150 are associated with increased proinflammatory mediator expression in Krüppel-like factor 2 (KLF2)-deficient macrophages. J Biol Chem 2014 289 31638 31646. doi: 10.1074/jbc.M114.579763.
110. Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalán-Campos J, Hartmann P, Thiemann A, Weber C, Schober A., The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1-and microRNA-155-dependent pathway during atherosclerosis. Circulation 2013 127 1609 1619. doi: 10.1161/CIRCULATIONAHA.112.000736.
111. Rossi RL, Rossetti G, Wenandy L, Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol 2011 12 796 803. doi: 10.1038/ni.2057.
112. Zernecke A., MicroRNAs in the regulation of immune cell functions-implications for atherosclerotic vascular disease. Thromb Haemost 2012 107 626 633. doi: 10.1160/TH11-08-0603.
113. Dunand-Sauthier I, Santiago-Raber ML, Capponi L, Vejnar CE, Schaad O, Irla M, Seguín-Estévez Q, Descombes P, Zdobnov EM, Acha-Orbea H, Reith W., Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function. Blood 2011 117 4490 4500. doi: 10.1182/blood-2010-09-308064.
114. Wang P, Hou J, Lin L, Wang C, Liu X, Li D, Ma F, Wang Z, Cao X., Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol 2010 185 6226 6233. doi: 10.4049/jimmunol.1000491.
115. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D., MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010 33 607 619. doi: 10.1016/j.immuni.2010.09.009.
116. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, Pierre P., MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA 2009 106 2735 2740. doi: 10.1073/pnas.0811073106.
117. Jurkin J, Schichl YM, Koeffel R, Bauer T, Richter S, Konradi S, Gesslbauer B, Strobl H., miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation. J Immunol 2010 184 4955 4965. doi: 10.4049/jimmunol.0903021.
118. Liu X, Zhan Z, Xu L, Ma F, Li D, Guo Z, Li N, Cao X., MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIα. J Immunol 2010 185 7244 7251. doi: 10.4049/jimmunol.1001573.
119. Doran AC, Meller N, McNamara CA., Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008 28 812 819. doi: 10.1161/ATVBAHA.107.159327.
120. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ, Owens GK., KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med 2015 21 628 637. doi: 10.1038/nm.3866.
121. Feil S, Fehrenbacher B, Lukowski R, Essmann F, Schulze-Osthoff K, Schaller M, Feil R., Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ Res 2014 115 662 667. doi: 10.1161/CIRCRESAHA.115.304634.
122. Vengrenyuk Y, Nishi H, Long X, Ouimet M, Savji N, Martinez FO, Cassella CP, Moore KJ, Ramsey SA, Miano JM, Fisher EA., Cholesterol loading reprograms the microRNA-143/145-myocardin axis to convert aortic smooth muscle cells to a dysfunctional macrophage-like phenotype. Arterioscler Thromb Vasc Biol 2015 35 535 546. doi: 10.1161/ATVBAHA.114.304029.
123. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L., miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet 2011 4 197 205. doi: 10.1161/CIRCGENETICS.110.958702.
124. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, Miano JM, Ivey KN, Srivastava D., miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009 460 705 710. doi: 10.1038/nature08195.
125. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, Richardson JA, Bassel-Duby R, Olson EN., MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009 23 2166 2178. doi: 10.1101/gad.1842409.
126. Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G., The knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009 16 1590 1598. doi: 10.1038/cdd.2009.153.
127. Boettger T, Beetz N, Kostin S, Schneider J, Krüger M, Hein L, Braun T., Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009 119 2634 2647. doi: 10.1172/JCI38864.
128. Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta N, Steer BM, Ingram AJ, Gupta M, Al-Omran M, Teoh H, Marsden PA, Verma S., MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012 126 S81 S90. doi: 10.1161/CIRCULATIONAHA.111.084186.
129. Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C., MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res 2007 100 1579 1588. doi: 10.1161/CIRCRESAHA.106.141986.
130. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, Deitch EA, Huo Y, Delphin ES, Zhang C., MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res 2009 105 158 166. doi: 10.1161/CIRCRESAHA.109.197517.
131. Liu X, Cheng Y, Yang J, Xu L, Zhang C., Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol 2012 52 245 255. doi: 10.1016/j.yjmcc.2011.11.008.
132. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A., Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem 2009 284 3728 3738. doi: 10.1074/jbc.M808788200.
133. Bazan HA, Hatfield SA, O'Malley CB, Brooks AJ, Lightell D Jr, Woods TC., Acute Loss of miR-221 and miR-222 in the Atherosclerotic Plaque Shoulder Accompanies Plaque Rupture. Stroke 2015 46 3285 3287. doi: 10.1161/STROKEAHA.115.010567.
134. Dentelli P, Rosso A, Orso F, Olgasi C, Taverna D, Brizzi MF., microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol 2010 30 1562 1568. doi: 10.1161/ATVBAHA.110.206201.
135. Wang D, Deuse T, Stubbendorff M, Local microRNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis. Arterioscler Thromb Vasc Biol 2015 35 1945 1953. doi: 10.1161/ATVBAHA.115.305597.
136. Davis BN, Hilyard AC, Lagna G, Hata A., SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008 454 56 61. doi: 10.1038/nature07086.
137. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S., Circulating microRNAs in patients with coronary artery disease. Circ Res 2010 107 677 684. doi: 10.1161/CIRCRESAHA.109.215566.
138. Weber M, Baker MB, Patel RS, Quyyumi AA, Bao G, Searles CD., MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB. Cardiol Res Pract 2011 2011 532915. doi: 10.4061/2011/532915.
139. Zhu GF, Yang LX, Guo RW, Liu H, Shi YK, Ye JS, Yang ZH., microRNA-155 is inversely associated with severity of coronary stenotic lesions calculated by the Gensini score. Coron Artery Dis 2014 25 304 310. doi: 10.1097/MCA.0000000000000088.
140. D'Alessandra Y, Carena MC, Spazzafumo L, Martinelli F, Bassetti B, Devanna P, Rubino M, Marenzi G, Colombo GI, Achilli F, Maggiolini S, Capogrossi MC, Pompilio G., Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. PLoS One 2013 8 e80345. doi: 10.1371/journal.pone.0080345.
141. Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, van Berkel TJ, Biessen EA., The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun 2010 394 792 797. doi: 10.1016/j.bbrc.2010.03.075.
142. Hulsmans M, Sinnaeve P, Van der Schueren B, Mathieu C, Janssens S, Holvoet P., Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J Clin Endocrinol Metab 2012 97 E1213 E1218. doi: 10.1210/jc.2012-1008.
143. Xiong XD, Cho M, Cai XP, Cheng J, Jing X, Cen JM, Liu X, Yang XL, Suh Y., A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression. Mutat Res 2014 761 15 20. doi: 10.1016/j.mrfmmm.2014.01.001.
144. Takahashi Y, Satoh M, Minami Y, Tabuchi T, Itoh T, Nakamura M., Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Clin Sci (Lond) 2010 119 395 405. doi: 10.1042/CS20100003.
145. Thygesen K, Alpert JS, Jaffe AS, Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction Third universal definition of myocardial infarction. Circulation 2012 126 2020 2035. doi: 10.1161/CIR.0b013e31826e1058.
146. Zeller T, Keller T, Ojeda F, Reichlin T, Twerenbold R, Tzikas S, Wild PS, Reiter M, Czyz E, Lackner KJ, Munzel T, Mueller C, Blankenberg S., Assessment of microRNAs in patients with unstable angina pectoris. Eur Heart J 2014 35 2106 2114. doi: 10.1093/eurheartj/ehu151.
147. D'Alessandra Y, Devanna P, Limana F, Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010 31 2765 2773. doi: 10.1093/eurheartj/ehq167.
148. Zile MR, Mehurg SM, Arroyo JE, Stroud RE, DeSantis SM, Spinale FG., Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients after myocardial infarction. Circ Cardiovasc Genet 2011 4 614 619. doi: 10.1161/CIRCGENETICS.111.959841.
149. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q., Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010 31 659 666. doi: 10.1093/eurheartj/ehq013.
150. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B., Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010 3 499 506. doi: 10.1161/CIRCGENETICS.110.957415.
151. Devaux Y, Mueller M, Haaf P, Goretti E, Twerenbold R, Zangrando J, Vausort M, Reichlin T, Wildi K, Moehring B, Wagner DR, Mueller C., Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med 2015 277 260 271. doi: 10.1111/joim.12183.
152. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, Corsten MF, Schroen B, Lair ML, Heymans S, Wagner DR., Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem 2012 58 559 567. doi: 10.1373/clinchem.2011.173823.
153. Olivieri F, Antonicelli R, Lorenzi M, D'Alessandra Y, Lazzarini R, Santini G, Spazzafumo L, Lisa R, La Sala L, Galeazzi R, Recchioni R, Testa R, Pompilio G, Capogrossi MC, Procopio AD., Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol 2013 167 531 536. doi: 10.1016/j.ijcard.2012.01.075.
154. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, Kempf T, Wollert KC, Thum T., Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011 51 872 875. doi: 10.1016/j.yjmcc.2011.07.011.
155. Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, Dong X, Qin S, Zhang C., A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010 119 87 95. doi: 10.1042/CS20090645.
156. Ai J, Zhang R, Li Y, Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010 391 73 77. doi: 10.1016/j.bbrc.2009.11.005.
157. Li YQ, Zhang MF, Wen HY, Hu CL, Liu R, Wei HY, Ai CM, Wang G, Liao XX, Li X., Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics (Sao Paulo) 2013 68 75 80
158. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J, Leidinger P, Meese E, Katus HA, Rottbauer W., MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011 106 13 23. doi: 10.1007/s00395-010-0123-2.
159. Wang F, Long G, Zhao C, Li H, Chaugai S, Wang Y, Chen C, Wang DW., Atherosclerosis-related circulating miRNAs as novel and sensitive predictors for acute myocardial infarction. PLoS One 2014 9 e105734. doi: 10.1371/journal.pone.0105734.
160. Feinberg MW., MicroRNAs as pathophysiological targets: an emerging nexus for personalized medicine in heart failure? Trends Cardiovasc Med 2016 26 111 114. doi: 10.1016/j.tcm.2015.06.001
161. Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M., Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013 62 2178 2184. doi: 10.1016/j.jacc.2013.07.081.
162. Mearns BM., Dyslipidemia: Phase III trial of mipomersen in heterozygous FH. Nat Rev Cardiol 2012 9 674. doi: 10.1038/nrcardio.2012.151.
163. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST., Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010 375 998 1006. doi: 10.1016/S0140-6736(10)60284-X.
164. Akdim F, Stroes ES, Sijbrands EJ, Tribble DL, Trip MD, Jukema JW, Flaim JD, Su J, Yu R, Baker BF, Wedel MK, Kastelein JJ., Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010 55 1611 1618. doi: 10.1016/j.jacc.2009.11.069.
165. Broderick JA, Zamore PD., MicroRNA therapeutics. Gene Ther 2011 18 1104 1110. doi: 10.1038/gt.2011.50.
166. Grünweller A, Hartmann RK., Locked nucleic acid oligonucleotides: the next generation of antisense agents? BioDrugs 2007 21 235 243
167. Flierl U, Nero TL, Lim B, Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J Exp Med 2015 212 129 137. doi: 10.1084/jem.20140391.
168. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S., Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012 3 1. doi: 10.1186/1758-907X-3-1.
169. van Rooij E, Olson EN., MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012 11 860 872. doi: 10.1038/nrd3864.
170. Semple SC, Akinc A, Chen J, Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010 28 172 176. doi: 10.1038/nbt.1602.
171. Love KT, Mahon KP, Levins CG, Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010 107 1864 1869. doi: 10.1073/pnas.0910603106.
172. Soutschek J, Akinc A, Bramlage B, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004 432 173 178. doi: 10.1038/nature03121.
173. Ebert MS, Neilson JR, Sharp PA., MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007 4 721 726. doi: 10.1038/nmeth1079.
174. Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ, van den Berg A., Generation of miRNA sponge constructs. Methods 2012 58 113 117. doi: 10.1016/j.ymeth.2012.07.019.
175. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT., MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011 13 423 433. doi: 10.1038/ncb2210.
176. Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, Ponzoni M, Naldini L., Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 2009 6 63 66. doi: 10.1038/nmeth.1277.
177. Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, Vetter R, Fechner H, Müller OJ., microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther 2011 18 199 209. doi: 10.1038/gt.2010.141.
178. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P., Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005 309 1577 1581. doi: 10.1126/science.1113329.
179. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Ørum H., Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010 327 198 201. doi: 10.1126/science.1178178.
180. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR., Treatment of HCV infection by targeting microRNA. N Engl J Med 2013 368 18 1685 1694. doi: 10.1056/NEJMoa1209026.
181. Janssen HL, Reesink HW, Zeuzem S, Lawitz E, Rodriguez-Torres M, Chen A, Davis C, King B, Levin AA, Hodges MR., A randomized, double-blind, placebo (plb) controlled safety and anti-viral proof of concept study of miravirsen (MIR), an oligonucleotide targeting miR-122, in treatment naíve patients with genotype 1 (gt1) chronic HCV infection. The 62nd annual meeting of the American Association for the Study of Liver Diseases. 2011 San Francisco, CA The Liver Meeting
182. Ling H, Fabbri M, Calin GA., MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013 12 847 865. doi: 10.1038/nrd4140.